Evaluation of the Efficacy of the Administration of COVID-19 Convalescent Plasma in Reducing the Progression to Severe Disease of Older Adults with Mild Symptoms due to SARSCOV2
Period: 2020
Researchers:
- Dr. Mabel Berrueta
- Lic. Luz Gibbons
- Lic. Eugenia Settecase
Objective: To evaluate the effectiveness of convalescent plasma in reducing progression to severe disease in people between 65-74 years of age with at least one comorbidity and in all those ≥ 75 years of age who present with mild symptoms of less than 48 hours of evolution at the time of onset. of the investigation and receive an early diagnosis of COVID-19.
Type of study: Randomized, double-blind, placebo-controlled study
Financing: INFANT Foundation